Marcie A. Goldstein

Davis Polk advised the underwriters in connection with the $55 million initial public offering of 3,666,667 shares of common stock of Ayala Pharmaceuticals, Inc. Ayala is traded on the…

Davis Polk advised the underwriter in connection with the initial public offering of 30,000,000 units of Sustainable Opportunities Acquisition Corp. for aggregate proceeds of $300…

Davis Polk advised the representatives of the several underwriters, in connection with the initial public offering of 36,000,000 units of CC Neuberger Principal Holdings I, including 5,400…

Davis Polk advised the representatives of the several underwriters in connection with a $587 million SEC-registered offering of 17,250,000 shares of common stock of Grocery Outlet…

Davis Polk advised the underwriters in connection with the $645 million public offering of 12,835,245 shares of Class A common stock of Tradeweb Markets Inc., which included 1,674,162…

Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,300,000 shares of its common stock. The common stock is listed on the…

Davis Polk advised the underwriters in connection with an initial public offering of 16,100,000 shares of common stock of Revolution Medicines, Inc. at $17.00 per share (which includes the…

Davis Polk advised the lead book-running managers in connection with the initial U.S. public offering of 6,000,000 common shares of TFI International, Inc. In addition, the underwriters…

Davis Polk advised the underwriters in connection with a $75 million public offering of common stock by RAPT Therapeutics, Inc. RAPT Therapeutics’ common stock is listed on the …

Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of common stock of Beam Therapeutics Inc. The common stock is listed on the…